Alexion

Alexion restructures, cuts workforce 20%

Wednesday, September 13, 2017

Alexion Pharmaceuticals announced an operational plan to re-align the global organization with its refocused corporate strategy. The plan is expected to deliver approximately $270 million in GAAP and approximately $250 million in non-GAAP pre-tax savings annually by 2019. The restructuring will reduce the company’s global workforce by approximately 20%. The resulting savings will allow Alexion to prioritize investments to advance growth opportunities, optimize capabilities across the organization, and position Alexion to deliver on its financial ambitions, including growing GAAP operating margin to 37% and non-GAAP operating margin to 50% in 2019.

[Read More]

Alexion and Sema4 announce strategic partnership

Friday, August 11, 2017

Alexion Pharmaceuticals, Inc. and Sema4 have announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery. This new partnership will combine Alexion’s rare disease SmartPanel analytics with Sema4’s proven success in next-generation sequencing and genomic interpretation to further enable novel diagnostic and therapeutic insights into rare diseases.

[Read More]

Alexion, Moderna end partnership

Tuesday, August 1, 2017

Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, provided an update on its rare disease Research & Development (R&D) strategy, issuing the following statement related to Alexion Pharmaceuticals R&D realignment announcement.

[Read More]

Alexion adds Orloff, Law and Franchini to leadership team

Monday, June 5, 2017

Alexion Pharmaceuticals announced key additions to its executive leadership team. Reporting to Chief Executive Officer Ludwig Hantson will be: John Orloff, M.D., executive vice president, head of Research & Development; Anne-Marie Law, executive vice president, chief human resources officer; and Indrani Lall Franchini, J.D., executive vice president, chief compliance officer.

[Read More]

Rady Children’s Institute, Alexion partner on genetic disorders

Wednesday, May 17, 2017

The Rady Children’s Institute for Genomic Medicine (RCIGM) and Alexion Pharmaceuticals announced a strategic partnership to accelerate the diagnosis of critically ill newborns with rare genetic disorders. The collaboration combines the Institute’s genomic research expertise with Alexion data science and bioinformatics capabilities to advance precision medicine for infants in an intensive care setting.

[Read More]

Agilis Biotherapeutics expands Commercial, Medical Teams

Tuesday, May 9, 2017

Agilis Biotherapeutics, a biotechnology company advancing innovative gene therapy products for the treatment of rare genetic diseases that affect the central nervous system (CNS), has expanded its commercial and medical teams, hiring Markus Peters, Ph.D., as chief commercial officer; Kirsten Gruis, M.D., as chief medical officer; and Anne Marie Conway, M.H.A, R.N., as vice president, Clinical Operations.

[Read More]

Alexion appoints Ludwig Hantson chief executive officer

Tuesday, March 28, 2017

Alexion Pharmaceuticals announced that its board of directors has appointed Ludwig N. Hantson, Ph.D., as chief executive officer and member of the board of directors, effective immediately. Dr. Hantson most recently served as president and CEO of Baxalta, a spin-off as a public company from Baxter, and a developer of therapies for orphan and underserved diseases in hematology, immunology and oncology. Dr. Hantson brings to Alexion a strong record of developing diverse rare disease pipelines and commercializing innovative and life-transformative therapies at industry-leading companies.

[Read More]

Dr. Andreas Rummelt joins supervisory board of Leukocare

Tuesday, July 19, 2016

Leukocare, a provider of stabilizing and protecting formulation technologies for biopharmaceuticals like biologics and vaccines, announced the election of Dr. Andreas Rummelt as new member of its supervisory board. Together with Dr. Jean-Paul Prieels, who held various executive positions at GlaxoSmithKline, former Sandoz CEO Dr. Rummelt is the second former executive from big pharma on the Leukocare board. 

[Read More]

Facing protocol amendments head-on

Friday, April 1, 2016

The unplanned costs and delays associated with protocol amendments have prompted many sponsor companies to identify new approaches to simplify protocol designs and reduce the frequency of protocol amendments over the course of the past few years. Yet a new Tufts Center for the Study of Drug Development (CSDD) analysis found that the majority of protocols still require substantial amendments, which led to significantly longer clinical trial cycle times and higher costs.

[Read More]